European Journal of Nuclear Medicine and Molecular Imaging

Article	Citations
EANM Springer Prizes 2020 awarded at EANM 2021	240
Towards molecular imaging-guided intervention theatres in oncology	183
“Fuzzy” radiomics: the way forward for nuclear medicine imaging applications?	154
New technologies—the best is yet to come	153
Nuclear imaging and therapy in oncology in Poland in 2021–2022	139
Highlights of the 34th EANM Annual Congress 2021, 2nd virtual edition: “FROM HAMBURG WITH LOVE”	134
New horizons for the World Federation of Nuclear Medicine and Biology: achievements, partnerships, and future directions	128
Intriguing information from recent letter and article regarding unwanted targeting of salivary glands by PSMA ligands	124
Correction to: Preclinical SPECT and PET: Joint EANM and ESMI procedure guideline for implementing an efficient quality control programme	122
Tumor agnostic ultrasmall nanoprobes for fluorescence-guided surgical resection in peritoneal metastasis	98
Cinematic rendering of [18F]FDG-PET/MR	98
Low-dose dobutamine stress gated blood pool SPECT assessment of left ventricular contractile reserve in ischemic cardiomyopathy: a feasibility study	89
Seasonal variation in D2/3 dopamine receptor availability in the human brain	87
Comparison of CT, MRI, and F-18 FDG PET/CT for initial N-staging of oral squamous cell carcinoma: a cost-effectiveness analysis	87
Real-time diagnosis of sampled lesions in targeted biopsy of prostate Cancer using a novel tracer [64Cu] Cu-DOTA-PSMA-3Q: a pilot preclinical study	86
A clinical study of a CD44v6-targeted fluorescent agent for the detection of non-muscle invasive bladder cancer	85
Updated practice guideline for dual-energy X-ray absorptiometry (DXA)	83
Cadherin-17 as a target for the immunoPET of adenocarcinoma	79
[68Ga]Ga-FAPI versus [18F]FDG PET/CT in the evaluation of Langerhans cell histiocytosis	76
A visual whole-body tumor-burden classification based on PSMA PET/CT to predict response to novel androgen receptor signaling inhibitors for metastatic hormone-sensitive prostate cancer patients	75
FAPI PET for monitoring of rheumatological treatment in multifocal peritoneal nodular fibrosis: a case study	73
Robust and generalizable artificial intelligence for multi-organ segmentation in ultra-low-dose total-body PET imaging: a multi-center and cross-tracer study	73
Simultaneous high-resolution whole-brain MR spectroscopy and [18F]FDG PET for temporal lobe epilepsy	71
Long-term impact of myocardial inflammation on quantitative myocardial perfusion—a descriptive PET/MR myocarditis study	70
Individual-level metabolic connectivity from dynamic [18F]FDG PET reveals glioma-induced impairments in brain architecture and offers novel insights beyond the SUVR clinical standard	70

[18F]Fluorocholine PET/MRI and [18F]Fluorocholine PET/CT as first- and second-line imaging in primary hyperparathyroidism – who takes the lead?	70
Infiltrative growth pattern of prostate cancer is associated with lower uptake on PSMA PET and reduced diffusion restriction on mpMRI	68
Correction to: Safety and dosimetry of [177Lu]Lu-DOTA-TATE in adolescent patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours, or pheochromocytomas and paragangli	67
Assessment of [18F]PI-2620 Tau-PET Quantification via Non-Invasive Automatized Image Derived Input Function	66
The feasibility of quantitative assessment of dynamic 18F-fluorodeoxyglucose PET in Takayasu’s arteritis: a pilot study	66
FAPI PET/CT in infectious, inflammatory, and rheumatological diseases: “watch it like a hawk” or “one swallow does not make a summer”?	65
Melanin-targeted [18F]-PFPN PET imaging may shed light for clear cell sarcoma	63
First-in-human imaging using [11C]MDTC: a radiotracer targeting the cannabinoid receptor type 2	63
68Ga-EMP-100 PET/CT—a novel ligand for visualizing c-MET expression in metastatic renal cell carcinoma—first in-human biodistribution and imaging results	62
Deep learning–based whole-body characterization of prostate cancer lesions on [68Ga]Ga-PSMA-11 PET/CT in patients with post-prostatectomy recurrence	62
Non-invasive visualization of liver fibrosis with [68Ga]Ga-DOTA-FAPI-04 PET from preclinical insights to clinical translation	61
Extended therapy with [177Lu]Lu-PSMA-617 in responding patients with high-volume metastatic castration-resistant prostate cancer	61
Excretion of glucose analogue with SGLT2 affinity predicts response effectiveness to sodium glucose transporter 2 inhibitors in patients with type 2 diabetes mellitus	60
Variabilities in global DNA methylation and β-sheet richness establish spectroscopic landscapes among subtypes of pancreatic cancer	60
Is PSMA PET/CT cost-effective for the primary staging in prostate cancer? First results for European countries and the USA based on the proPSMA trial	60
[68 Ga]Ga-FAPI versus [18F]F-FDG in malignant melanoma: complementary or counterpoint?	58
Feasibility and therapeutic potential of [177Lu]Lu-FAPI-2286 in patients with advanced metastatic sarcoma	57
Application of artificial intelligence in nuclear medicine and molecular imaging: a review of current status and future perspectives for clinical translation	57
Brain perfusion estimation by Tikhonov model-free deconvolution in a long axial field of view PET/CT scanner exploring five different PET tracers	56
PSMA expression and PSMA PET/CT imaging in metastatic soft tissue sarcoma patients, results of a prospective study	56
Prospective clinical study of sentinel node detection in bladder cancer using a hybrid tracer – Towards replacement of pelvic lymph node dissection in cases with sentinel node visualization on SPECT/C	55
Vancomycin-based tracers guiding in situ visualization of bacteria on osteosynthesis devices and surgical debridement	55
Clinical, dosimetric, and reporting considerations for Y-90 glass microspheres in hepatocellular carcinoma: updated 2022 recommendations from an international multidisciplinary working group	54
Positron emission tomography in the diagnosis and follow-up of transthyretin amyloid cardiomyopathy patients: A systematic review	49
TMTV-Net: fully automated total metabolic tumor volume segmentation in lymphoma PET/CT images — a multi-center generalizability analysis	48
Abdelhamid H. Elgazzar, Synopsis of Pathophysiology in Nuclear Medicine, Second Edition	48
Andrea Varrone, Silvia Morbelli, Valentina Garibotto (Editors). Clinical nuclear medicine in neurology. An Atlas of challenging cases.	48
Assessment of cerebral drug occupancy in humans using a single PET-scan: A [11C]UCB-J PET study	47
Lisa Bodei, Jason S. Lewis, Brian M. Zeglis (Editors): Radiopharmaceutical Therapy	47
Promise of hypoxia-targeted tracers in metastatic lymph node imaging	47
Diffusely increased breast uptake of [18F]AlF-NOTA-FAPI-04 related to menstrual status in a patient with papillary thyroid cancer	46
Comparison of two hybrid sentinel node tracers: indocyanine green (ICG)-99mTc-nanocolloid vs. ICG-99mTc-nanoscan from a nuclear medicine and surgical perspective	46
Abnormal localized [18F]FDG accumulation in a Hoffman 3D brain phantom caused by Pseudomonas aeruginosa and Stenotrophomonas maltophilia	45
Development of STING probes and visualization of STING in multiple tumor types	45
Distinguishing benign lesions from malignant ones using FAPI-based tracers: will we need to bid farewell to dual-time points imaging?	44
Intense [68Ga]Ga-FAPI-04 uptake of pancreatic microcystic serous cystadenoma mimicking malignancy	44
PSMA-targeted radioligand therapy with [177Lu]Lu-LNC1011 for metastatic castration-resistant prostate cancer: a pilot study	43
Imaging biomarkers of cortical neurodegeneration underlying cognitive impairment in Parkinson’s disease	42
A single-center, multi-factor, retrospective study to improve the diagnostic accuracy of primary prostate cancer using [68Ga]Ga-PSMA-11 total-body PET/CT imaging	42
[68Ga]Ga-NOTA-T4 ImmunoPET imaging for evaluating TROP2 expression in patients with solid tumors	42
Targeting of immune checkpoint regulator V-domain Ig suppressor of T-cell activation (VISTA) with 89Zr-labelled CI-8993	42
Brachytherapy at the nanoscale with protein functionalized and intrinsically radiolabeled [169Yb]Yb2O3 nanoseeds	42
Molecular radiotherapy for adult type metastatic neuroendocrine tumours in children	42
Moganshan international consensus on further strengthening global scientific collaboration in the field of molecular imaging	42
About ESTMABLE2: non-inferiority doesn’t equal better	42
Impact of extended [177Lu] Lu-PSMA-617 therapy on absorbed kidney dose and CKD-EPI values: how long can therapy be safely continued?	41
Preclinical evaluation and pilot clinical study of [68Ga]Ga-NOTA-H006 for non-invasive PET imaging of 5T4 oncofetal antigen	41
STING-targeted PET tracer for early assessment of tumor immunogenicity in colorectal cancer after chemotherapy	41
Increased incidence of primary metastatic prostate cancer in the era of PSMA PET/CT: a population-based analysis	40
Preclinical and first‑in‑human evaluation of [68Ga]Ga-DOTA-PEG2-Asp2-PDL1P PET imaging to assess tumor PD-L1 expression	40

Correction to: Targeting of immune checkpoint regulator V-domain Ig suppressor of T-cell activation (VISTA) with 89Zr-labelled CI-8993	39
Deep learning-based image reconstruction and post-processing methods in positron emission tomography for low-dose imaging and resolution enhancement	39
A cutting-edge technology for the future of nuclear medicine	39
An artificial intelligence-driven image quality assessment system for whole-body [18F]FDG PET/CT	39
Correction to: A bis-boron boramino acid PET tracer for brain tumor diagnosis	38
Correction to: FDG-PET/CT in colorectal cancer: potential for vascular-metabolic imaging to provide markers of prognosis	38
Intraoperative molecular imaging of colorectal lung metastases with SGM-101: a feasibility study	38
[18F]-mFBG imaging for COVID-19-induced cardiac sympathetic innervation impairment	38
Validation of simplified uptake measures against dynamic Patlak Ki for quantification of lesional 89Zr-Immuno-PET antibody uptake	38
Multi-modality deep learning-based [68Ga]Ga-DOTA-FAPI-04 PET polar map generation: potential value in detecting reactive fibrosis after myocardial infarction	37
Comparative assessment of radiation therapy–induced vasculitis using [18F]FDG-PET/CT in patients with non-small cell lung cancer treated with proton versus photon radiotherapy	37
Immunohistochemical ERG positivity is associated with decreased PSMA expression and lower visibility in corresponding [68Ga]Ga-PSMA-11 PET scans of primary prostate cancer	37
Sentinel lymph node detection in thyroid carcinoma using [68Ga]Ga-tilmanocept PET/CT: a proof-of-concept study	37
Bilateral intense [68 Ga]Ga-PSMA‑11 uptake in cyproterone acetate induced gynecomastia	37
Development of a novel molecular probe for visualizing mesothelin on the tumor via positron emission tomography	37
68Ga-DOTATOC digital-PET imaging of inflammatory cell infiltrates in myocarditis following COVID-19 vaccination	36
Atypical [18F]FDG avidity in ALK-positive anaplastic large cell lymphoma: diagnostic and monitoring potential of [18F]FAPI PET/CT	36
Patterns of PET-positive residual tissue at interim restaging and risk of treatment failure in advanced-stage Hodgkin’s lymphoma: an analysis of the randomized phase III HD18 trial by the German Hodgk	35
[18F]AlF-NOTA-FAPI-04 PET/CT uptake in metastatic lesions on PET/CT imaging might distinguish different pathological types of lung cancer	35
Advancements in non-invasive visualization of the immune checkpoint TIGIT: a systematic review	35
DNA damage and repair in peripheral blood mononuclear cells after internal ex vivo irradiation of patient blood with 131I	35
Improved FAPI-radiopharmaceutical pharmacokinetics from the perspectives of a dose escalation study	35
A hybrid radioactive and fluorescence approach is more than the sum of its parts; outcome of a phase II randomized sentinel node trial in prostate cancer patients	35
Immuno-PET of colorectal cancer with a CEA-targeted [68 Ga]Ga-nanobody: from bench to bedside	34
Disrupted gut microecology after high-dose 131I therapy and radioprotective effects of arachidonic acid supplementation	34
Distinct metabolic patterns of neuropsychiatric systemic lupus erythematosus on hierarchical cluster analysis	34
Chinese management guidelines for radioactive iodine-refractory differentiated thyroid cancer (2025 edition)	34
Comparison of the diagnostic efficacy of 68 Ga-FAPI-04 PET/MR and 18F-FDG PET/CT in patients with pancreatic cancer	34
Parkinson’s Disease-Related pattern in isolated REM sleep behaviour disorder as a prodromal progression marker: 8-Year Follow-Up changes assessed at three time points	34
Commentary to “[68 Ga]Ga-FAPI-04 PET/CT on assessing Crohn’s disease intestinal lesions” by Chen and colleagues	34
Targeted alpha therapy: a comprehensive analysis of the biological effects from “local-regional-systemic” dimensions	34
Forearm metastasis as solitary manifestation of recurrent prostate cancer: A challenge for standard PSMA PET imaging protocol	34
Guiding principles on the education and practice of theranostics	34
Identifying and navigating bottlenecks in the translation of novel radiopharmaceuticals: a perspective	34
Interpretable multimodal deep learning model for predicting post-surgical international society of urological pathology grade in primary prostate cancer	34
First results on kinetic modelling and parametric imaging of dynamic 18F-FDG datasets from a long axial FOV PET scanner in oncological patients	34
PET imaging of new target CDK19 in prostate cancer	34
Comparison of PSMA immunohistochemistry scoring systems to parametric [18F]PSMA-1007 PET/MRI in primary prostate cancer	34
From radiotracer to radiopharmaceutical: a philosophical approach	34
[68Ga]Ga-DOTA-FAPI-04 PET/CT depicts metastases from medullary thyroid cancer that [68Ga]Ga-DOTATOC PET/CT missed	34
Comparison of PET/CT using 68Ga-NOTA-Exendin-4 with 68Ga-DOTATATE, 18F-FDG, and conventional imaging in the localization of insulinomas	33
Intelligent ultrafast total-body PET for sedation-free pediatric [18F]FDG imaging	33
[177Lu]Lu-FAP-2286 therapy in ovarian neuroendocrine carcinoma: a promising theranostic approach	33
Longitudinal evaluation of five nasopharyngeal carcinoma animal models on the microPET/MR platform	33
Multicentric development and evaluation of [18F]FDG PET/CT and CT radiomic models to predict regional and/or distant recurrence in early-stage non-small cell lung cancer treated by stereotactic body r	33
Correction to: [18F]FDG brain PET findings in CLIPPERS at diagnosis and therapeutic follow-up	33
Prognostic role of metabolic parameters (MTV and TLG) of staging PET/CT in the pediatric population with Hodgkin’s lymphoma: an open discussion	32
Size-changeable nanoprobes for the combined radiotherapy and photodynamic therapy of tumor	32
First-in-human validation of a DROP-IN β-probe for robotic radioguided surgery: defining optimal signal-to-background discrimination algorithm	32
Evaluation of long axial field-of-view (LAFOV) PET/CT for post-treatment dosimetry in Yttrium-90 radioembolization of liver tumors: a comparative study with conventional SPECT imaging	32
Reply to Vaz et al., Editorial Commentary: Should “Heterogeneous response” be considered as new category for assessing treatment response in patients with breast cancer?	32
Exploring the value of FAP-targeted PET/CT in differentiating breast cancer molecular subtypes: a preliminary study	32
European guidelines update on PSMA PET/CT for prostate cancer staging—snap back to reality	32
Molecular imaging: The bridge from human phenome to personalized precision medicine	32
Comparative analysis of [18F]F-FAPI PET/CT, [18F]F-FDG PET/CT and magnetization transfer MR imaging to detect intestinal fibrosis in Crohn’s disease: A prospective animal model and human cohort study	31
Extended nodal radiotherapy for prostate cancer relapse guided with [11C]-choline PET/CT: ten-year results in patients enrolled in a prospective trial	31
Assessing non-invasive quantitative methods for [18F]SynVesT-1 PET imaging of synaptic vesicle glycoprotein 2A in the rat brain	31
Diagnostic performance of deep learning models for detecting bone metastasis on whole-body bone scan in prostate cancer	31
A rationally designed nuclei-targeting FAPI 04-based molecular probe with enhanced tumor uptake for PET/CT and fluorescence imaging	31
Can Q.Clear reconstruction be used to improve [68 Ga]Ga-DOTANOC PET/CT image quality in overweight NEN patients?	31
Non-invasive molecular imaging for precision diagnosis of metastatic lymph nodes: opportunities from preclinical to clinical applications	31
Amyloid pathology related to aberrant structure-function coupling of brain networks in Alzheimer’s disease: insights from [18F]-florbetapir PET imaging	30
Radioembolization of hepatocellular carcinoma with 90Y glass microspheres: an earlier administration day unexpectedly improves tumour control probability	30
Correction to: Deep learning for improving PET/CT attenuation correction by elastic registration of anatomical data	30
Radiofrequency ablation for autonomously functioning nodules as treatment for hyperthyroidism: subgroup analysis of toxic adenoma and multinodular goitre and predictors for treatment success	30
Pre-symptomatic scintigraphic and genetic cascade screening in cardiac transthyretin amyloidosis	30
Quantitative 18F-FDG PET/CT Model for predicting pathological complete response to neoadjuvant immunochemotherapy in NSCLC: comparison with RECIST 1.1 and PERCIST	30
Machine learning predictive performance evaluation of conventional and fuzzy radiomics in clinical cancer imaging cohorts	30
Comparison of 64Cu-DOTA-PSMA-3Q and 64Cu-NOTA-PSMA-3Q utilizing NOTA and DOTA as bifunctional chelators in prostate cancer: preclinical assessment and preliminary clinical PET/CT imaging	30
Association of PET vascular activity score with Takayasu’s arteritis angiographic progression	30
PET/CT with [68Ga]Ga-TEoS-DAZA for localization of a traumatic biliary leak	30
Pre-operative dual-time-point [18F]FET PET differentiates CDKN2A/B loss and PIK3CA mutation status in adult-type diffuse glioma: a single-center prospective study	30
Comparisons of treatment performance and therapy sequences in neuroendocrine neoplasms using progression-free survival ratios	29
Visual grading for noninvasive assessment of transthyretin-related cardiomyopathy with bone scintigraphy: time for moving forward?	29
Non-prostate cancer tumours: incidence on 18F-DCFPyL PSMA PET/CT and uptake characteristics in 1445 patients	29
Longitudinal preclinical evaluation of the novel radioligand [11C]CHDI-626 for PET imaging of mutant huntingtin aggregates in Huntington’s disease	28
Development and characterisation of [18F]TTDP, a novel T cell immunoglobulin and ITIM domain tracer, in humanised mice and non-human primates	28
Near-infrared II theranostic agents for the diagnosis and treatment of Alzheimer’s disease	28
Personalised PET imaging in oncology: an umbrella review of meta-analyses to guide the appropriate radiopharmaceutical choice and indication	28
Comparison of the diagnostic value of [68 Ga]Ga-FAPI-04 PET/MR and [18F]FDG PET/CT in patients with T stage ≤ 2a2 uterine cervical cancer: a prospective study	28

Intraprocedural MRI-based dosimetry during transarterial radioembolization of liver tumours with holmium-166 microspheres (EMERITUS-1): a phase I trial towards adaptive, image-controlled treatment del	28
Prognostic value of PSMA PET/CT-Based local staging in predicting biochemical recurrence after radical prostatectomy	28
PET imaging utilization and trends in Germany: a comprehensive survey	28
The first international network symposium on artificial intelligence and informatics in nuclear medicine: “The bright future of nuclear medicine is illuminated by artificial intelligence”	28
Cardiac [99mTc]Tc-hydroxydiphosphonate uptake on bone scintigraphy in patients with hereditary transthyretin amyloidosis: an early follow-up marker?	28
Identification of a CEACAM5 targeted nanobody for positron emission tomography imaging and near-infrared fluorescence imaging of colorectal cancer	28
Assessment of viable tumours by [68Ga]Ga-FAPI-04 PET/CT after local regional treatment in patients with hepatocellular carcinoma	28
A comparative study of [68Ga]Ga-FAPI-04 PET/MR and [18F]FDG PET/CT in the diagnostic accuracy and resectability prediction of ovarian cancer	27
Correction to: Coronavirus (COVID-19) pandemic mediated changing trends in nuclear medicine education and training: time to change and scintillate	27
Early response monitoring during [177Lu]Lu-PSMA I&T therapy with quantitated SPECT/CT predicts overall survival of mCRPC patients: subgroup analysis of a Swiss-wide prospective registry study	27
CXCR4-directed PET/CT with [68 Ga]Ga-pentixafor in solid tumors—a comprehensive analysis of imaging findings and comparison with histopathology	27
Classification of 18F-Flutemetamol scans in cognitively normal older adults using machine learning trained with neuropathology as ground truth	27
Prognostic utility of RECIP 1.0 with manual and AI-based segmentations in biochemically recurrent prostate cancer from [68Ga]Ga-PSMA-11 PET images	27
Correction to: Modelling [18F]LW223 PET data using simplified imaging protocols for quantification of TSPO expression in the rat heart and brain	27
The accuracy and intra- and interobserver variability of PSMA PET/CT for the local staging of primary prostate cancer	27
The diagnostic performance of [18F]Florbetazine in Alzheimer’s disease: a head-to-head comparison to [11C]PiB and [18F]Florbetapir	27
First-in-man study of the PSMA Minibody IR800-IAB2M for molecularly targeted intraoperative fluorescence guidance during radical prostatectomy	27
Hypermetabolic pulmonary lesions detection and diagnosis based on PET/CT imaging and deep learning models	27
Clinical and pathological predictors for FDG-PET/CT avidity in patients with marginal zone lymphoma—a retrospective cohort study	27
Beyond 68Ga-labeled somatostatin analogues: is it time to say goodbye to [68Ga]DOTA-conjugated peptides for neuroendocrine neoplasms?	26
Impact of Tafamidis on [99mTc]Tc-pyrophosphate Scintigraphy in Ala97Ser Hereditary Transthyretin amyloid cardiomyopathy: significant initial reduction with stable Long-Term effects	26
Myocardial perfusion SPECT findings in postCOVID period	26
Subendocardial quantification enhances coronary artery disease detection in 18F-flurpiridaz PET	26
Collection on molecular imaging in cardiac amyloidosis	26
Correction to: Co‑clinical FDG‑PET radiomic signature in predicting response to neoadjuvant chemotherapy in triple‑negative breast cancer	26
Targeting tumour surface collage with hydrogel probe: a new strategy to enhance intraoperative imaging sensitivity and stability of bladder cancer	26
Abbreviated scan protocols to capture 18F-FDG kinetics for long axial FOV PET scanners	26
Astatine-211 for PSMA-targeted α-radiation therapy of micrometastatic prostate cancer: a sustainable approach towards precision oncology	26
Whole-body tumour burden on [18F]DCFPyL PET/CT in biochemical recurrence of prostate cancer: association with tumour biology and PSA kinetics	26
The eye-black sign of lower eyelids related to R-CHOP therapy: a rare imaging pitfall	25
Chlorin e6-loaded goat milk-derived extracellular vesicles for Cerenkov luminescence-induced photodynamic therapy	25
Risk of primary breast cancer in patients with differentiated thyroid cancer undergoing radioactive iodine therapy: a systematic review and meta-analysis	25
DICOM header editing, between possibilities and regulatory bounds– 40 years of DICOM “standard”	25
The value of serial [⁶⁸Ga]Ga-FAPI-04 PET/CT in predicting pathological response and evaluating therapeutic efficacy to neoadjuvant chemotherapy in breast cancer	25
18F-sodium fluoride PET-CT visualizes both axial and peripheral new bone formation in psoriatic arthritis patients	25
Efficiency of succinylated gelatin and amino acid infusions for kidney uptake reduction of radiolabeled αvβ6-integrin targeting peptides: considerations on clinical safety profiles	25
Second primary malignancy risk in thyroid cancer and matched patients with and without radioiodine therapy analysis from the observational health data sciences and informatics	25
Impact of deep learning denoising on kinetic modelling for low-dose dynamic PET: application to single- and dual-tracer imaging protocols	25
Exploring the metabolic landscape of lung adenocarcinoma and squamous cell carcinoma: a total-body [18F]FDG PET/CT approach	25
Genomic instability is associated with response to [¹⁷⁷Lu]Lu-PSMA-I&T radioligand therapy: an exploratory, preliminary liquid biopsy analysis	25
PSMA-targeted theranostics of solid tumors: applications beyond prostate cancers	25
Efficacy of combined targeted radionuclide therapy and immune checkpoint Inhibition in animal tumour models: a systematic review and meta-analysis of the literature	25
Long axial field of view (LAFOV) PET-CT: implementation in static and dynamic oncological studies	25
[68Ga]Ga-FAPI PET/CT imaging of brown tumors in a patient with primary hyperparathyroidism	24
Decoupling of regional neural activity and inter-regional functional connectivity in Alzheimer’s disease: a simultaneous PET/MR study	24
Head-to-head comparison of [68 Ga]Ga-P16-093 and [68 Ga]Ga-PSMA-617 in dynamic PET/CT evaluation of the same group of recurrent prostate cancer patients	24
Staging of prostate Cancer with ultra-fast PSMA-PET scans enhanced by AI	24
New thresholds in semi-quantitative [18F]FDG PET/CT are needed to assess large vessel vasculitis with long-axial field-of-view scanners	24
PET imaging of animal models with depressive-like phenotypes	24
Preoperative assessment of pancreatic cancer with [68Ga]Ga-DOTA-FAPI-04 PET/MR versus [18F]-FDG PET/CT plus contrast-enhanced CT: a prospective preliminary study	24
Interleukin-6 as surrogate marker for imaging-based hypoxia dynamics in patients with head-and-neck cancers undergoing definitive chemoradiation—results from a prospective pilot trial	24
Expert consensus on workflow of PET/CT with long axial field-of-view	24
Whole pelvis vs. hemi pelvis elective nodal radiotherapy in patients with PSMA-positive nodal recurrence after radical prostatectomy - a retrospective multi-institutional propensity score analysis	24
PET imaging with [¹¹C]CHDI-00485180-R, designed as radioligand for aggregated mutant huntingtin, in people with Huntington’s disease	24
In vivo methods for imaging blood–brain barrier function and dysfunction	23
A phase I/II study of the safety and efficacy of [177Lu]Lu-satoreotide tetraxetan in advanced somatostatin receptor-positive neuroendocrine tumours	23
Early changes of PSMA PET expression after initiation of androgen receptor signaling inhibitors in CRPC: an international multicenter retrospective study	23
Total-body pediatric PET is ready for prime time	23
L.J. Koenig, D. Tamimi, S.E. Perschbacher, H. Demirturk. Diagnostic imaging: oral and maxillofacial. 3rd Edition	23
A. Zaheer, S.P. Raman, M.L. Rosado-de-Christenson, S. Martínez-Jiménez, S.H. Garrana, G. Fananapazir, D. Rogers, B.R. Foster: Imaging Anatomy: Chest, Abdomen, Pelvis, 3rd Edition	23
FAPI PET uptake patterns after invasive medical interventions: a single center retrospective analysis	23
Adoption of Lutetium-177 PSMA radioligand therapy for metastatic castration resistant prostate cancer: a total population analysis in Germany from 2016 to 2020	23
Lymph node classification in E-PSMA reporting guidelines for PSMA-PET	23
The role of radiographers in nuclear medicine; the link between patient and technology	23
Hybrid training in nuclear medicine: where are we going to?	23
Pleasurable music activates cerebral µ-opioid receptors: a combined PET-fMRI study	23
Role of brain 2-[18F]fluoro-2-deoxy-D-glucose-positron-emission tomography as survival predictor in amyotrophic lateral sclerosis	23
Connectivity based on glucose dynamics reveals exaggerated sensorimotor network coupling on subject-level in Parkinson’s disease	23
Exploring coronary microvascular function by quantitative CZT-SPECT: a small step or giant leap for INOCA patients?	23
Prostate-specific membrane antigen radioguided surgery with negative histopathology: an in-depth analysis	23
Deep learning–based denoising of low-dose SPECT myocardial perfusion images: quantitative assessment and clinical performance	22
Prospective intra-individual blinded comparison of [18F]PSMA-1007 and [68 Ga]Ga-PSMA-11 PET/CT imaging in patients with confirmed prostate cancer	22
An ultra-small organic dye nanocluster for enhancing NIR-II imaging-guided surgery outcomes	22
Positive amyloid and tau PET in an early-onset Alzheimer’s disease with a rare PSEN1 (Arg278Gly) mutation	22
Impressive FDG PET/CT image of extensive peripheral nervous system involvement for T-lymphoblastic leukemia/lymphoma	22
To give or not to give? A critical appraisal of a clinical trial on radioiodine treatment	22
How to attract young talent to nuclear medicine step 1: a survey conducted by the EANM Oncology and Theranostics Committee to understand the expectations of the next generation	22
Loss of synaptic density in nucleus basalis of meynert indicates distinct neurodegeneration in Alzheimer’s disease: the RJNB-D study	22
Neuroimaging biomarkers in the biological definition of Parkinson’s disease and dementia with Lewy bodies – EANM position on current state, unmet needs and future perspectives	22
ImmunoPET imaging of Trop2 expression in triple-negative breast cancer using [64Cu]Cu-NOTA-Trodelvy-F(ab’)2	22
Eribulin improves tumor oxygenation demonstrated by 18F-DiFA hypoxia imaging, leading to radio-sensitization in human cancer xenograft models	22
The prognostic role of next-generation imaging-driven upstaging in newly diagnosed prostate cancer patients	22
High-resolution pediatric age–specific 18F-FDG PET template: a pilot study in epileptogenic focus localization	22
Three-phase bone quantitative-SPECT of navicular bones with a high-sensitivity whole-body CZT-camera in a Müeller-Weiss syndrome	22
Enhancing predictability of IDH mutation status in glioma patients at initial diagnosis: a comparative analysis of radiomics from MRI, [18F]FET PET, and TSPO PET	22
Letter to the Editor: Postoperative thyroglobulin as a yard-stick for radioiodine therapy: decision tree analysis in a European multicenter series of 1317 patients with differentiated thyroid cancer	22
Hematologic toxicity profile and efficacy of [225Ac]Ac-PSMA-617 α-radioligand therapy of patients with extensive skeletal metastases of castration-resistant prostate cancer	22
Correction to: Hetero-bivalent agents targeting FAP and PSMA	22
Pigmented villonodular synovitis detected by [68Ga]Ga-FAPI-04 PET/CT	22
Correction To: Coronary artery calcium measurement on attenuation correction computed tomography using artificial intelligence: correlation with coronary flow capacity and prognosis	22
Comparative evaluation of a novel [18F] F-Labeled PET tracer XTR004 against [13N] ammonia in myocardial perfusion imaging for coronary artery disease	22
Myocardial flow reserve derived from D-SPECT for evaluating non-culprit ischemic lesions in STEMI patients: comparison with quantitative flow ratio	22
Joint EANM, SNMMI and IAEA enabling guide: how to set up a theranostics centre	22
[18F]FDG-PET accurately identifies pathological response early upon neoadjuvant immune checkpoint blockade in head and neck squamous cell carcinoma	21
Utilizing artificial intelligence to detect cardiac amyloidosis in patients with severe aortic stenosis: A step forward to diagnose the underdiagnosed	21